Vaccine shows promise in preventing cervical cancer return
NCT ID NCT02405221
First seen Oct 31, 2025 · Last updated May 22, 2026 · Updated 30 times
Summary
This early study tested a vaccine called TA-CIN in 15 people who had been treated for HPV16-related cervical cancer and were cancer-free at the start. The goal was to see if the vaccine is safe and can boost the body's immune response against the virus. Researchers measured side effects and checked for antibodies and T-cells in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV16 ASSOCIATED CERVICAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21287, United States
-
Women & Infants Center, University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
Conditions
Explore the condition pages connected to this study.